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Aims Stroke is a leading cause of morbidity and mortality, and its incidence increases with age. Both in animals and in
humans, oxidative stress appears to play an important role in ischaemic stroke, with or without reperfusion. The
adaptor protein p66Shc is a key regulator of reactive oxygen species (ROS) production and a mediator of ischae-
mia/reperfusion damage in ex vivo hearts. Hence, we hypothesized that p66Shc may be involved in ischaemia/reperfu-
sion brain damage. To this end, we investigated whether genetic deletion of p66Shc protects from ischaemia/
reperfusion brain injury.
Methods
and results
Transient middle cerebral artery occlusion (MCAO) was performed to induce ischaemia/reperfusion brain injury in
wild-type (Wt) and p66Shc knockout mice (p66Shc2/2), followed by 24 h of reperfusion. Cerebral blood flow and
blood pressure measurements revealed comparable haemodynamics in both experimental groups. Neuronal
nuclear antigen immunohistochemical staining showed a significantly reduced stroke size in p66Shc2/2 when com-
pared with Wt mice (P, 0.05, n ¼ 7–8). In line with this, p66Shc2/2 mice exhibited a less impaired neurological func-
tion and a decreased production of free radicals locally and systemically (P, 0.05, n ¼ 4–5). Following MCAO,
protein levels of gp91phox nicotinamide adenine dinucleotide phosphate oxidase subunit were increased in brain
homogenates of Wt (P, 0.05, n ¼ 4), but not of p66Shc2/2 mice. Further, reperfusion injury in Wt mice induced
p66Shc protein in the basilar and middle cerebral artery, but not in brain tissue, suggesting a predominant involvement
of vascular p66Shc.
Conclusion In the present study, we show that the deletion of the ageing gene p66Shc protects mice from ischaemia/reperfusion
brain injury through a blunted production of free radicals. The ROS mediator p66Shc may represent a novel thera-
peutical target for the treatment of ischaemic stroke.
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Introduction
Stroke is a leading global cause of mortality, responsible for more
deaths than cancer.1 Even in patients presenting comparable
degrees of ischaemia, a huge variability in the recovery of brain
function is observed, indicating a complex pathological process
which, to date, still lacks a specific therapy for its effective treat-
ment.2 Indeed, even reopening of the stroke-related artery with
either thrombolysis or catheter intervention is still far from provid-
ing a safe and effective therapy for the majority of patients. It thus
appears crucial to elucidate the molecular mechanisms underlying
the pathogenesis of neuronal injury after stroke to set the basis for
the design of novel effective therapeutical strategies.
Reactive oxygen species (ROS) are considered as crucial players
in cerebrovascular disease.3,4 Several animal and human studies
showed an association between ischaemic stroke and increased
systemic and local production of ROS.5 –9 A large body of evi-
dence indicates nicotinamide adenine dinucleotide phosphate
oxidase (NADPH oxidase) as a major source of ROS generation
in cerebrovascular disease.3,10 In line with this, NADPH oxidase
expression is profoundly greater in the vessel wall of cerebral
arteries rather than systemic arteries11 and its genetic deletion
in mice reduces brain infarction.12 Recently, NADPH oxidase
has been shown to be a downstream target of the adaptor
protein p66Shc.13
The mammalian p66Shc adaptor protein, together with p46Shc
and p52Shc, belongs to ShcA adaptor/docking protein family,
which plays an important role in transducing activation signals
from receptors, such as growth factor, cytokines, and integrins,
to downstream signalling cascades.14,15 Among the three isoforms,
p46Shc and p52Shc are important in the regulation of growth factor-
induced Ras/Erk signalling,14,15 whereas p66Shc is crucially involved
in ROS generation and translates oxidative stress into apoptosis.14
Genetic deletion of p66Shc in mice extends lifespan by 30%16 and
slows down the progression of atherogenesis in double-mutant
p66Shc2/2/ApoE2/2 mice fed on a high fat diet.17,18 Deletion of
p66Shc also protects from hyperglycaemia-induced endothelial dys-
function,19,20 reduces fat accumulation and premature death in
adipose tissue,21,22 and attenuates glomerulopathy23,24 in diabetic
mice. The reported protective effects achieved by p66Shc deletion
are mainly due to reduced oxidative stress, improved insulin sensi-
tization, increased mitochondrial uncoupling, and reduced trigly-
ceride accumulation.17 –19,21– 27 In line with this, increased levels
of p66Shc mRNA have been reported in peripheral blood mono-
nuclear cells of type-2 diabetic patients25 and in patients with
acute myocardial infarction.28 Enhanced expression of p66Shc has
been reported in ethanol-induced liver damage in mice,29
chronic kidney dysfunction in spontaneous hypertension rats30
and aged rats,30 and HIV-1-induced cell apoptosis in podocyte,31
which is associated with a lower level of ROS production and a
blunted activation of NFkappaB.29,30 Of note, deletion of p66Shc
was also shown to protect ex vivo-perfused murine hearts from is-
chaemia/reperfusion-induced injury32; however, the involvement of
p66Shc in stroke is largely unknown.
In the present study, we thus analysed the effects of genetic de-
letion of p66Shc in ischaemia/reperfusion brain injury. In particular,
we investigated whether p66Shc knockout mice are protected from
ischaemia/reperfusion-induced and ROS-mediated brain injury and
neurological deficits.
Methods
Animal model
Experiments were performed on 12–14-week-old wild-type (Wt)
(C57Bl6J) and p66Shc male knockout mice (p66Shc2/2). Animals
were fed on a normal chow diet and had ad libitum access to food
and water and were maintained at 248C under a 12 h light/dark
cycle. Study design and experimental protocols were approved by
the institutional animal care committee (Licence no. TVA 139_2008;
Kommission fu¨r Tierversuche des Kantons Zu¨rich, Switzerland).
Middle cerebral artery occlusion model
and haemodynamics measurements
To induce ischaemia/reperfusion brain injury, a transient middle cere-
bral artery occlusion (MCAO) surgery was performed on both
p66Shc2/2 and Wt mice as previously described.33 Mice were initially
anaesthetized with 4% of isoflurane and then maintained on 1.5% iso-
furane vaporized in NO2 and O2 (2:1). Following a midline cervical in-
cision, the left common carotid artery (CCA), external artery (ECA),
and internal carotid artery (ICA) were carefully exposed under an op-
erating microscope. Thereafter, a 6-0 silicone-coated filament (Doccol
Corporation, Redlands, CA, USA) was introduced into the CCA and
advanced into the ICA 9–12 mm from the common carotid bifurca-
tion. Rectal temperature was maintained at 37+ 0.58C while the
animals were under anaesthesia through the use of circulating water
pads. The thread was left in place for 60 min. After the removal of
the thread and wound care, animals were carefully observed and
cared for and left in their cages for the next 24 h. The same procedure
was performed for sham-operated animals. However, the silicone-
coated filament was advanced into the ICA 5 mm from the
common carotid bifurcation, without interruption of cerebral blood
flow (CBF) in the middle cerebral artery. During anaesthesia, regional
CBF (rCBF) in the area of the cortex supplied by the MCA was mea-
sured using laser Doppler flowmetry (PeriFluxSystem 5000 with probe
model no. 418-1, Perimed AB, Ja˘rfa˘lla, Sweden). The microtip probe
was positioned and glued 2 mm posterior and 6 mm lateral to the
bregma.
For blood pressure measurements, mice were allowed to familiarize
with the procedure and equipment for a period of 1 week and then
systolic (SBP) and diastolic blood pressure (DBP) and heart rate
were recorded using the tail-cuff method (model LE 5002, Storage
Pressure Meter, Letica, Spain).
MCAO experiments were performed blindly.
Neurological deficit measurement
Neurological deficit measurement was performed after 1 and 24 h of
reperfusion following MCAO, using a four-point scale based on the
Bederson test34: normal motor function was scored as 0, flexion of
the contralateral torso and forelimb on lifting the animal by the tail
as 1, circling to the contralateral side but normal posture at rest as
2, leaning to the contralateral side at rest as 3, and no spontaneous
motor activity as 4. Neurological deficit measurements were per-
formed by two people independently in a blinded way.
Stroke size measurement
Following 24 h of reperfusion, mice were sacrificed and perfused with
PBS and relevant organs were excised. Brains were immersed in 4%
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formalin in phosphate buffer overnight and transferred to 30% sucrose
solution for at least 3 days. Next, coronal 30 mm-thick sections were
cut on a freezing microtome (Leica, Nussloch, Germany). Stroke size
was measured by immunohistochemical neuronal nuclear antigen
(NeuN) as previously performed (Dilution 1:100, Millipore, Temecula,
CA, USA).35 Quantification of stroke size was performed using the
NIH ImageJ software.
Western blotting
Protein expression was determined by western blot analysis. Isolated
brains, basilar arteries, and middle cerebral arteries were homogenized
in lysis buffer (NaCl 150 mmol/L, EDTA 1 mmol/L, NaF 1 mmol/L,
DTT 1 mmol/L, aprotinin 10 mg/mL, leupeptin 10 mg/mL, Na3VO4
0.1 mmol/L, PMSF 1 mmol/L, and NP-40 0.5%). Protein concentration
was measured according to the manufacturer’s recommendations
(Bio-Rad Laboratories GmbH, Mu¨nchen, Germany). Equal amounts
of protein were separated on a 10% SDS–PAGE and transferred
onto a polyvinylidene fluoride membrane (Millipore, Volketswil, Switz-
erland) by semi-dry transfer. Antibodies against gp91phox, p67phox,
and p47phox (all from Upstate) were used at 1:500 dilution.
Anti-Shc (Cell Signaling, Danvers, MA, USA) was used at 1:1000 dilu-
tion. Blots were normalized to a-tubulin (1:20 000 dilution, Sigma)
or glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression
(1:20 000 dilution, Millipore, Temecula, CA, USA). Anti-rabbit and anti-
mouse secondary antibodies were purchased from GE Healthcare
(Buckinghamshire, UK). For the detection of protein carbonylation,
dinitrophenol antibody (LifeSpan BioSciences, Inc.) at 1:200 dilution
was used. All western blots were quantified by densitometric analysis
performed using the Scion Image Corporation software.
Measurement of reactive oxygen species
O2
2 production in whole blood was determined using the spin
trap 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethyl-pyrrolidine
(Noxygen, Germany). Blood samples were mixed with Krebs-HEPES
solution containing sodium diethyldithiocarbamate trihydrate (5 mmol/L),
deferoxamine methanesulfonate (25 mmol/L), and 1-hydroxy-3-
methoxycarbonyl-2,2,5,5-tetramethyl-pyrrolidine (200 mmol/L) (all
from Noxygen, Germany), and heparin (100 U/mL). Samples were
frozen in liquid nitrogen, and O2
2 production was assessed with an
ESR spectrometer (Bruker, Bremen, Germany) with the following
instrumental settings: centre field: 3485 G; sweep width: 50.000 G;
static field: 3477 G; microwave frequency: 9.76 GHz; microwave
power: 19.91 mW; modulation amplitude: 2.60 G; modulation fre-
quency: 86.00 kHz; sweep time: 5.24 s; number of scans: 10.
Statistical analysis
Data are given as mean+ SEM. Statistical analysis was done by two-way
ANOVA analysis of variance with post hoc multiple comparisons using the
Bonferroni test, or paired/unpaired t-test in a two-tailed way as appropri-
ate. A probability value P, 0.05 denoted a significant difference. Statis-
tical analyses were performed using the GraphPad Prism software
version 4.03 (GraphPad Software, Inc., La Jolla, CA, USA).
Results
Reduced brain infarction after ischaemia/
reperfusion injury in p66Shc2/2 mice
To evaluate the role of p66Shc in ischaemia/reperfusion brain injury,
a transient MCAO surgery was performed on both p66Shc2/2 and
Wt mice in order to induce a focal ischaemic stroke. Middle
cerebral artery occlusion is a reliable and reproducible rodent
model of cerebral ischaemia in humans that has been demon-
strated to result in sensorimotor and cognitive deficits.33 Following
60 min of MCA occlusion, the silicone filament was withdrawn,
allowing reperfusion for 24 h. Following 24 h of reperfusion,
both p66Shc2/2 (P, 0.0001) and Wt (P ¼ 0.0086) mice under-
went a comparable weight loss (data not shown). To quantify
stroke size, NeuN immunohistochemical staining was performed
as previously described.35 Morphometrical analysis revealed a sig-
nificantly reduced stroke size in p66Shc2/2 mice compared with
Wt mice (Wt: 42.84+6.05 mm2 vs. p66Shc2/2: 16.66+
7.95 mm2; *P ¼ 0.0196; n ¼ 7–8; Figure 1A). Sham-operated Wt
and p66Shc2/2 did not display any lesions (data not shown).
Genetic deletion of p66Shc improves
neurological function following middle
cerebral artery occlusion
For the assessment of neurological function after MCAO, we
performed a Bederson-based four-point scale test. After 1 h of
reperfusion, both Wt and p66Shc2/2 mice exhibited marked co-
ordination dysfunction, shown as decreased activity, imbalance of
movement, and decreased gripping ability (Wt: 1.87+0.26 vs.
p66Shc2/2: 1.43+0.17; P ¼ NS; n ¼ 14; Figure 1B). Following
24 h of reperfusion, p66Shc2/2 mice showed an improved neuro-
logical function compared with Wt mice (Wt: 1.53+0.19 vs.
p66Shc2/2: 0.89+ 0.33; *P ¼ 0.0142; n ¼ 14; Figure 1B). Moreover,
neurological deficit score of p66Shc2/2 was improved at 24 h com-
pared with 1 h of reperfusion (24 h: 0.89+0.33 vs. 1 h: 1.43+
0.17; #P ¼ 0.0130; n ¼ 14; Figure 1B). Such improvement was not
observed in Wt mice (24 h: 1.53+ 0.19 vs. 1 h: 1.87+ 0.26; P ¼
0.2449; n ¼ 14; Figure 1B), suggesting an improved recovery poten-
tial in p66Shc2/2 mice. Both Wt and p66Shc2/2 sham-operated
mice did not exhibit any neurological deficit at 1 or 24 h (data
not shown).
Comparable cerebral perfusion
and systemic blood pressure in wild-type
and p66Shc2/2 mice
Regional cerebral blood flow was recorded during MCAO proced-
ure using laser Doppler flowmetry. Basal rCBF was comparable
between Wt and p66Shc2/2 mice. Following the ligation of the
CCA, a comparable reduction in blood flow was observed in
both experimental groups (Wt: 249.6+ 2.69% vs. p66Shc2/2:
251.67+9.37%; Figure 2A); similarly, after the insertion of the
silicon thread to achieve MCAO, a comparable degree of rCBF re-
duction compared with basal level was recorded in Wt and
p66Shc2/2 mice, indicating a comparable degree of MCA occlusion
in both groups (Wt: 284.86+2.49% vs. p66Shc2/2: 286.13+
2.77%; Figure 2A). Finally, upon the retraction of the silicone
thread, a comparable re-establishment of blood flow was observed
in both Wt and p66Shc2/2 mice (Wt: 53.58+ 6.82% vs. p66Shc2/2:
48.41+ 11.41%; P ¼ NS for all time points; n ¼ 6–7; Figure 2A).
In order to exclude possible interference on stroke size by dif-
ferent systemic blood pressure in the two strains, blood pressure
and heart rate were measured. No differences in SBP and DBP as
well as in heart rate were observed in both experimental groups
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Figure 2 Cerebral blood flow and arterial blood pressure measurements. (A) Laser Doppler measurements revealed no difference in regional
cerebral blood flow before middle cerebral artery occlusion (MCAO) between wild-type and p66Shc2/2 mice and showed a similar alteration
upon middle cerebral artery occlusion and reperfusion. (B–D) Wild-type (Wt) and p66Shc2/2 mice do not differ in systolic and diastolic blood
pressure (SBP, DBP) as well as in heart rate.
Figure 1 Stroke size and neurological deficit measurement after ischaemia/reperfusion brain injury. (A) Representative neuronal nuclear
antigen immunohistochemical staining 24 h after middle cerebral artery occlusion (MCAO) in wild-type (Wt) and p66Shc2/2 mice. Arrows in-
dicate subcortical and cortical infarct components. p66Shc2/2 mice show reduced stroke size compared with wild-type mice, *P ¼ 0.0196.
Values are given as cubic millimetre. (B) The Bederson test. Neurological deficit was measured either at 1 h of reperfusion or at 24 h of reperfu-
sion. p66Shc2/2 stroke mice show improved neurological function at 24 h of reperfusion compared with wild-type stroke mice and with
p66Shc2/2 stroke mice at 1 h of reperfusion. *P ¼ 0.0142 for wild-type stroke (24 h) vs. p66Shc2/2 stroke mice (24 h). #P ¼ 0.0130 for
p66Shc2/2 stroke (24 h) vs. p66Shc2/2 stroke (1 h).
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(SBP: Wt: 154+ 9.866 mmHg vs. p66Shc2/2: 146.7+8.212 mmHg;
P ¼ NS; Figure 2B; DBP: Wt: 124+ 8.083 mmHg vs. p66Shc2/2:
128.7+7.219 mmHg; P ¼ NS; Figure 2C; heart rate: Wt:
508.3+3.930 b.p.m. vs. p66Shc2/2: 518.7+ 3.283 b.p.m.; P ¼
NS; Figure 2D).
Ischaemia/reperfusion injury-induced
local and systemic oxidative stress
is reduced in p66Shc2/2 mice
To address the role of oxidative stress, its level was quantified in
whole-brain homogenates after ischaemia/reperfusion by measur-
ing total protein carbonylation. Protein carbonylation is a widely
accepted index of oxidative stress and the most common post-
translational protein modification induced by oxidative stress. Is-
chaemia/reperfusion injury induced a significant increase in
protein carbonylation in the brain of Wt stroke mice compared
with that of sham-operated Wt mice (Wt stroke: 207.1+ 40.3%
vs. Wt sham: 100%; *P, 0.05; n ¼ 4; Figure 3A). In contrast, no
change in brain oxidative stress levels after ischaemia/reperfusion
was observed in p66Shc2/2 stroke mice compared with shams
(p66Shc2/2 stroke: 99.62+14.48% vs. p66Shc2/2 sham: 72.77+
18.17%; P ¼ NS; n ¼ 3–5; Figure 3A).
To determine levels of systemic oxidative stress following is-
chaemia/reperfusion injury, O2
2 levels were measured in whole
blood using electron spin resonance spectroscopy. Wild-type
stroke mice showed increased ROS generation after 24 h of
reperfusion compared with Wt sham mice (0.068+ 0.009 vs.
0.032+0.005 nmol; *P, 0.01; n ¼ 4–6; Figure 3B). In contrast,
p66Shc2/2 stroke mice displayed comparable levels of ROS to
p66Shc2/2 sham mice (0.025+ 0.003 vs. 0.043+ 0.009 nmol;
P ¼ NS; n ¼ 3–5; Figure 3B).
Increased protein levels of gp91phox
nicotinamide adenine dinucleotide
phosphate oxidase subunit in wild-type
mice after middle cerebral artery
occlusion
Nicotinamide adenine dinucleotide phosphate oxidase is a well-
known major source for ROS production in cerebrovascular
disease as well as a downstream target of p66Shc; to this end, its
expression was measured in brain homogenates 24 h after
MCAO. In the present study, protein expression of gp91phox
NADPH oxidase subunits, but not of p67phox and p47phox,
was significantly increased in the brain of Wt stroke mice com-
pared with that of Wt sham mice (gp91phox: Wt stroke: 348+
69.49% vs. Wt sham: 100%; *P, 0.05; n ¼ 4; Figure 4A). Interest-
ingly, this increase was not observed in the brain of p66Shc2/2
stroke mice compared with that of p66Shc2/2 sham ones
(gp91phox: p66Shc2/2 stroke: 108.5+ 18.09% vs. p66Shc2/2
sham: 50.14+11.73%; P ¼ NS; n ¼ 3–5; Figure 4A). In contrast,
p67phox (p67phox: Wt stroke: 427.1+ 139.1% vs. Wt sham:
100%; P ¼ NS; n ¼ 3–5; Figure 4B) and p47phox (data not
shown) NADPH oxidase subunit protein expression did not
change in any of the experimental groups.
To exclude possible involvement of other pro-/anti-oxidant
enzymes, we looked at protein expression of COX-2, SOD1,
Figure 3 Production of free radicals locally (brain) and systemically (in whole blood). (A) Wild-type (Wt) mice, but not p66Shc2/2 mice, show
increased brain protein carbonylation after ischaemia/reperfusion brain injury. Values are given as percentage of wild-type sham-operated mice.
*P, 0.05 for wild-type stroke vs. wild-type sham. (B) Electron spin resonance spectroscopy measured increased O2
2 levels in whole blood
of wild-type stroke mice but not in p66Shc2/2. Values are given as nmol O2
2. *P, 0.05 for wild-type stroke vs. wild-type sham.
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SOD2, and Gpx and found no significant differences in the levels of
these proteins in Wt stroke vs. p66Shc2/2 stroke groups (data not
shown).
Following ischaemia/reperfusion, p66Shc
protein is increased in the basilar artery
and middle cerebral artery but not in the
whole brain
To determine the regulation of p66Shc expression in cerebral
tissues following ischaemia/reperfusion, western blotting analysis
was performed. p66Shc protein expression in the basilar artery of
Wt stroke mice was profoundly increased compared with Wt
sham mice (Wt stroke: 615.4+257.1% vs. Wt sham: 100+
15.26%; *P ¼ 0.0245; n ¼ 7–8; Figure 5A). In line with this, p66Shc
protein levels in the middle cerebral artery of Wt stroke mice
were also elevated compared with Wt sham mice (Figure 5B). In
sharp contrast, hardly any p66Shc expression was detected in
whole-brain homogenates and most importantly its levels
remained unchanged after ischaemia/reperfusion (Figure 5C).
Discussion
The present study demonstrates for the first time that genetic de-
letion of the adaptor protein p66Shc2/2 protects mice from ischae-
mia/reperfusion-induced brain injury and consequent neurological
deficits. This effect is paralleled by a blunted activation of the
pro-oxidant enzyme NADPH oxidase, a downstream target of
p66Shc, and a reduced production of free radicals.
Transient occlusion of the middle cerebral artery is a well-
established model of stroke.36 Indeed, in our study, this approach
led to sizeable strokes and a reproducible neurological deficit.
Interestingly, genetic deletion of p66Shc protected mice from is-
chaemia/reperfusion-induced brain injury. Following 1 h occlusion
and 24 h of reperfusion, p66Shc2/2 displayed an over 50% reduc-
tion in cortical and subcortical brain lesions compared with Wt
mice. Our findings expand a previous report showing that p66Shc
deletion is protective against ischaemia/reperfusion injury in ex
vivo-perfused hearts32 to an in vivo setting on a different organ.
Assessment of neurological deficit 1 h after MCAO denoted a
similar degree of impairment in both Wt and p66Shc2/2 mice.
However, following 24 h of reperfusion, p66Shc2/2 mice displayed
a marked improvement in neuromotor function compared with
Wt mice. This indicates that (i) the protective effects of
p66Shc2/2 deletion interfere primarily with reperfusion injury
and not with the effects of ischaemia and (ii) that these effects
lead to a better neurological recovery after brain reperfusion. In
order to exclude a possible interference by different blood pres-
sure values and/or different degree of occlusion–reperfusion, we
measured blood pressure, heart rate as well as rCBF in all experi-
mental groups. Indeed, all haemodynamic values were comparable
in Wt and p66Shc2/2 mice, indicating that the observed effect is
not the result of gross physiological or procedural differences.
These findings are of potential clinical importance, as reperfusion
injury with subsequent brain oedema is an important complication
after successful thrombolysis in patients presenting with ischaemic
stroke.37,38 Nevertheless, stroke size and neurological impairment
were only examined at 24 h; although early time points are crucial,
showing a preserved protective effect at later time points would be
important for future developments based on the herein reported
data.
Increased production of ROS is widely recognized as a key me-
diator of reperfusion-induced brain injury,2,9,39,40 and protein car-
bonylation is an established marker of oxidative stress as well as
the most common post-translational protein modification
induced by oxidative stress.41,42 Here, we report that Wt stroke
mice show an increased carbonylation of brain proteins compared
with Wt sham-operated mice, demonstrating that ischaemia/
Figure 4 Protein levels of nicotinamide adenine dinucleotide phosphate oxidase subunits in whole-brain homogenates. Western blotting
reveals increased protein expression of gp91phox nicotinamide adenine dinucleotide phosphate oxidase subunit in brain homogenates of wild-
type (Wt) stroke mice, but not of p66Shc2/2 (A). In contrast, p67phox nicotinamide adenine dinucleotide phosphate oxidase subunit expression
does not change in any of the experimental groups (B). Values are given as percentage of wild-type sham. *P, 0.05 for wild-type stroke vs.
wild-type sham.
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reperfusion injury indeed induces oxidative stress.5– 8 In contrast,
brain tissue of p66Shc2/2 stroke mice did not display increased
levels of protein carbonylation compared with p66Shc2/2 shams
or Wt shams, suggesting that p66Shc is crucially involved in this
process. In the light of the important role played by ROS in ischae-
mia/reperfusion-induced brain injury,39,43 strategies aimed at pre-
venting their increase following reperfusion are currently being
sought for.2,39 Following ischaemia, increased levels of ROS
promote endothelial activation and increase the permeability of
brain arteries, leading to the expression of adhesion molecules,
pro-inflammatory cytokines, and increased leucocyte adhesion,
all of which are recognized mechanisms influencing stroke
size.39,40,43 Indeed, p66Shc2/2 stroke mice displayed a reduced gen-
eration of ROS and a reduced stroke size. In patients with ischae-
mic stroke, increased ROS levels have been measured also in
circulating blood.9 In line with this, we found increased levels of
O2
2 in peripheral blood of Wt stroke mice, but not in p66Shc2/2
stroke mice, suggesting a systemic activation of ROS-producing
pathways under these conditions. Although oxidative stress is cru-
cially implicated in the pathogenesis of cerebrovascular disease,
previous large clinical trials aimed at reducing ROS failed to
improve the outcome.44,45 Several factors could be taken into
account to explain this failure: (i) high concentration of antioxidant
supplements has been introduced in daily human diet due to signifi-
cant improvement of healthcare; (ii) endogenous antioxidant
defence systems may be depressed by additional antioxidant treat-
ment; (iii) exogenous antioxidant agent may function differently
from endogenous ones; and (iv) intracellular ROS production
sites may be sequestered in organelles (for instance, mitochon-
dria), thus preventing dietary antioxidants to reach their putative
site of action.46 Hence, the development of treatment strategies
such as prevention of p66Shc activation to prevent increased
ROS production, rather than lowering it, may represent a more ef-
fective alternative.
Nicotinamide adenine dinucleotide phosphate oxidase is a
membrane-bound enzyme known to be expressed in cerebral ar-
teries47,48 and recognized as a major source of ROS production in
cerebrovascular disease.3,10,11 Nicotinamide adenine dinucleotide
phosphate oxidase expression is known to increase in disease con-
ditions such as ischaemia,49,50 and its genetic deletion in mice was
shown to reduce brain infarction12; furthermore, NADPH oxidase
was recently reported to be a downstream target of p66Shc.13 In
line with the above, protein expression of gp91phox NADPH
oxidase subunit, but not of p67phox and p47phox, was strongly
increased following ischaemia/reperfusion in the brain of Wt
stroke mice. However, this increase was not observed in
p66Shc2/2 stroke mice, supporting previous reports that p66Shc
is an upstream regulator of NADPH oxidase and that the p66Shc/
NADPH oxidase axis is crucial for ischaemia/reperfusion-induced
ROS.13 To further support this associative finding, we also
looked at protein expression of other anti- or pro-oxidant
enzymes such as COX-2, SOD1, SOD2, and Gpx and found no sig-
nificant differences in the levels of these in Wt stroke and
p66Shc2/2 stroke groups (data not shown). Yet, the exact mechan-
isms linking p66Shc and NAPDH oxidase deserve further
investigation.
The mammalian ShcA adaptor protein is ubiquitously
expressed51 –54; however, p66Shc is hardly detectable in the
central nervous system,55–57 with exception of the developing
brain57 and cultured rat neurons.58 Indeed, in the present study,
p66Shc protein expression was hardly detectable in whole-brain
homogenates. Moreover, whole-brain p66Shc expression remained
unchanged following ischaemia/reperfusion, suggesting a minor in-
volvement of cerebral p66Shc. In sharp contrast, we found that the
Figure 5 p66Shc protein levels in the basilar artery, middle cerebral artery, and brain. (A and B) p66Shc protein expression is increased in
basilar artery and middle cerebral artery of wild-type (Wt) stroke mice compared with wild-type sham mice. (C) Protein level of p66Shc in
whole-brain homogenates is hardly detectable and remains comparable between wild-type stroke and wild-type sham mice. Values are
given as percentage of wild-type sham mice. *P ¼ 0.0245 for wild-type stroke vs. wild-type sham.
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basilar artery and the middle cerebral artery display higher levels of
basal p66Shc expression compared with the whole brain. Further-
more, p66Shc expression in the basilar and middle cerebral arteries
was dramatically increased following ischaemia/reperfusion, sug-
gesting that cerebrovascular rather than neuronal p66Shc may be
an important mediator of ischaemia/reperfusion brain injury. Our
findings could be partially explained by previous reports indicating
a pivotal role of the cerebral vasculature in determining stroke size.
Indeed, following reperfusion, the endothelium of cerebral arteries
is focally activated, thereby promoting leucocyte leakage into the
extracellular matrix and inflammation both of which are important
mechanisms determining neuronal damage.36,40 The crucial role of
cerebral arteries in determining stroke size was also recently
underscored by Yin et al.,36 who showed that vascular-specific de-
letion of PPARd increases stroke size in the mouse via an increased
post-ischaemic inflammation. In further support of our interpret-
ation is the fact that preserved endothelial function has been
described as the most common mechanism protecting p66Shc2/2
mice in several disease models, including diabetes,19 atheroscler-
osis,18 and ageing,20,26,59,60 where ROS are known to play an im-
portant role.
In summary, this study shows for the first time that genetic de-
letion of p66Shc strongly reduces stroke size following ischaemia/
reperfusion brain injury. In line with this, p66Shc2/2 mice displayed
a far milder neurological deficit following ischaemia/reperfusion
compared with Wt. The observed protective effects are likely
mediated by a reduced activation of the p66Shc target NADPH
oxidase which leads to a decreased production of free radicals. In-
hibition of this novel pathway may be a novel and effective thera-
peutic target in preventing reperfusion injury in patients presenting
with ischaemic stroke undergoing thrombolysis of interventional
reperfusion therapy.
Study limitations
There are some limitations that need to be acknowledged and
addressed regarding the present study. First of all, the use of
knock out animals does not completely exclude the possibility of
some adaptive mechanisms of compensatory nature taking place
over the course of their life. Second, the observed blunted activa-
tion of NAPDH subunits observed in p66Shc2/2 stroke mice needs
to be investigated further to elucidate the pathways involved.
Lastly, in order to fully support our conclusions with respect
to possible clinical applications, future studies including later
time points as well as larger animal models and human proof-
of-principle experiments should be conducted.
Perspectives
Over the last century, an impressive increase in human life expect-
ancy occurred; hence, also due to constant birth rates, the
population is ageing. With ascending age, the incidence of cerebro-
vascular diseases, such as stroke, sharply increases. Although
stroke is a leading cause of morbidity and mortality to date, no ef-
fective therapeutical strategy exists. In the present study, we have
shown for the first time that genetic deletion of p66Shc protects
mice from ischaemia/reperfusion brain injury through a blunted ac-
tivation of NADPH oxidase and a reduced production of free radi-
cals. Hence, p66Shc represents an interesting novel target to be
investigated in the context of ischaemic stroke and reperfusion
injury.
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